Imunon Inc. recently faced a potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement and minimum stockholders' equity requirement. The company received a delisting determination letter on May 28, 2025, indicating that unless a hearing was requested, trading of its common stock would be suspended on June 6, 2025. Imunon Inc. requested a hearing on May 29, 2025, to appeal the delisting determination and seek a suspension of delisting pending its return to compliance. The hearing request has stayed the suspension of trading, allowing the company's stock to remain listed on Nasdaq until the Panel delivers a decision. In a positive development, warrant exercises provided Imunon Inc. with $2.0 million in proceeds, raising its stockholders' equity to $3.0 million as of May 31, 2025.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。